CGP-35949 (sodium)

• Description:

  CGP-35949 sodium is a LTD4 antagonist with phospholipase inhibitory activity. CGP-35949 sodium can be used for research of asthma[1].

• UNSPSC:

  12352005

• Target:

  Leukotriene Receptor; Phospholipase

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cgp-35949-sodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC(C)=C(NC(C2=NN=N[N-]2)=O)C=C1OCCCOC3=CC=C(C(C)=O)C(O)=C3CCC.[Na+]

• Molecular Formula:

  C23H25ClN5NaO5

• Molecular Weight:

  509.92

• References & Citations:

  [1]Beck A, et al. CGP 35949, an LTD4 antagonist with phospholipase inhibitory activity: a new approach to the treatment of asthma. Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:771-4.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [111130-13-3]